Disruptions in supply chain and logistics increased. FY22 was an important year as invested in capacities across segments. Remain affirmative on $1bn revenues in FY23. healthy growth in formulations of +13% YoY for FY22. Received final approval for Lopinavir+Ritonavircombination and launched in US market.
Doing wonderful job👍